Evidence map›Paper›PMID 29050494›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2017

Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples.

Xuan Dung Ho, Phuong Phung, Van Q Le, Van H Nguyen, Ene Reimann, Ele Prans, Gea Kõks, Katre Maasalu, Nghi Tn Le, Le H Trinh and 3 more

Abstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. UpregulatedImmunoTargets and therapy · 2026
    Article
  8. Article
  9. Single-cell sequencing uncovers sensory neuron-mediated CGRP signaling as a driver of sarcoma progression.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Xuan Dung Ho1 Department of Oncology, 155407 College of Medicine and Pharmacy , Hue University, Hue 53000, Vietnam.ORCID http://orcid.org/0000-0001-7779-0088
Phuong Phung1 Department of Oncology, 155407 College of Medicine and Pharmacy , Hue University, Hue 53000, Vietnam.
Van Q Le3 Department of Oncology, Hanoi Medical University, Hanoi 15000, Vietnam.
Van H Nguyen3 Department of Oncology, Hanoi Medical University, Hanoi 15000, Vietnam.
Ene Reimann2 Department of Pathophysiology, 37546 University of Tartu , Tartu 50411, Estonia.
Ele Prans2 Department of Pathophysiology, 37546 University of Tartu , Tartu 50411, Estonia.
Gea Kõks2 Department of Pathophysiology, 37546 University of Tartu , Tartu 50411, Estonia.
Katre Maasalu5 Department of Traumatology and Orthopedics, 37546 University of Tartu , Tartu 50411, Estonia.
Nghi Tn Le7 Department of Orthopedics, 155407 College of Medicine and Pharmacy , Hue University, Hue 53000, Vietnam.
Le H Trinh3 Department of Oncology, Hanoi Medical University, Hanoi 15000, Vietnam.
Hoang G Nguyen3 Department of Oncology, Hanoi Medical University, Hanoi 15000, Vietnam.
Aare Märtson5 Department of Traumatology and Orthopedics, 37546 University of Tartu , Tartu 50411, Estonia.
Sulev Kõks2 Department of Pathophysiology, 37546 University of Tartu , Tartu 50411, Estonia.
Hanoi Medical University · VNHue University · VNEstonian University of Life Sciences · EETartu University Hospital · EEUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We performed whole transcriptome analysis of osteosarcoma bone samples. Initially, we sequenced total RNA from 36 fresh-frozen samples (18 tumoral bone samples and 18 non-tumoral paired samples) matching in pairs for each osteosarcoma patient. We also performed independent gene expression analysis of formalin-fixed paraffin-embedded samples to verify the RNAseq results. Formalin-fixed paraffin-embedded samples allowed us to analyze the effect of chemotherapy. Data were analyzed with DESeq2, edgeR and Reactome packages of R. We found 5365 genes expressed differentially between the normal bone and osteosarcoma tissues with an FDR below 0.05, of which 3399 genes were upregulated and 1966 were downregulated. Among those genes, BTNL9, MMP14, ABCA10, ACACB, COL11A1, and PKM2 were expressed differentially with the highest significance between tumor and normal bone. Functional annotation with the reactome identified significant changes in the pathways related to the extracellular matrix degradation and collagen biosynthesis. It was suggested that chemotherapy may induce the modification of ECM with important collagen biosynthesis. Taken together, our results indicate that changes in the degradation of extracellular matrix seem to be an important mechanism of osteosarcoma and efficient chemotherapy induces the genes related to bone formation. Impact statement Osteosarcoma is a rare disease but it is of interest to many scientists all over the world because the current standard treatment still has poor results. We sequenced total RNA from 36 fresh-frozen paired samples (18 tumoral bone samples and 18 non-tumoral paired samples) from osteosarcoma patients. We found that differences in the gene expressions between the normal and affected bones reflected the changes in the regulation of the degradation of collagen and extracellular matrix. We believe that these findings contribute to the understanding of OS and suggest ideas for further studies.

Indexed as

Gene Expression Regulation, NeoplasticAdolescentAdultAgedAged, 80 and overBone and BonesBone NeoplasmsChildFemaleGene Expression ProfilingHumansMaleMiddle AgedOsteosarcomaSequence Analysis, RNATranscriptomegene expression profilinghigh-through put nucleotide sequencingosteogenic sarcomaOsteosarcomaRNA sequencingtranscriptome

Identifiers

PMID29050494
PMCPMC5714151
OpenAlexW2765217312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.